This article, published in Vaccine, reviews the history of pneumococcal vaccines with a focus on the first heptavalent conjugated pneumococcal vaccine (PCV7), which was first licensed in the United States in 2000, followed by many other countries. After 11 years of use, the data confirm that PCV7 introduction resulted in a major reduction of S. pneumoniae invasive pneumococcal disease, non-bacteremic pneumonia, otitis media medical visits, the need for tympanic tubes, the number of cases of otorrhea, and of various antimicrobial resistant strains in children less than five years of age. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)
Author(s): Arguedas A, Soley C, Abdelnour A
Visit web page (English)
(Located at www.sciencedirect.com)
Citation: Arguedas A, Soley C, Abdelnour A. Prevenar Experience. Vaccine. 2011;29(Supplement 3):C26-34.